ClinicalTrials.Veeva

Menu

A Study Comparing Hypofractionated Dose Escalated VMAT to Conventional CCRT in Locally Advanced Head and Neck Cancer

Cairo University (CU) logo

Cairo University (CU)

Status

Unknown

Conditions

Locally Advanced Head and Neck Cancer

Treatments

Radiation: Hypofractionated dose escalated VMAT

Study type

Interventional

Funder types

Other

Identifiers

NCT03699969
HN12016

Details and patient eligibility

About

To compare efficacy and toxicity between hypofractionated dose escalated VMAT versus conventional concurrent chemoradiation in locally advanced head and neck cancer

Full description

patients were randomized to receive either: 70Gy in 35fx in 7wks at 2Gy/fx concurrently with weekly cisplatin 40mg/m2 (Arm A) or 74Gy in 33 fractions (fx) in 6.5 weeks at 2.24Gy/fx (Arm B). Volumetric Modulated Arc Therapy (VMAT) plans were created for both treatment arms

Enrollment

63 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥18 years and ≤70 years old.
  2. Histopathologically confirmed squamous cell carcinoma of head and neck.
  3. Locally advanced tumors (T3-T4 &/or N1-3) (stage IIB, III and stage IV-A: Staging by AJCC 7th edition).
  4. Patients not exposed to radical surgery for current disease.
  5. Performance status (ECOG) 2 or less.
  6. No associated co-morbidity with contraindication to chemotherapy.
  7. Normal Hemogram. (ANC ≥1.5x109/L, Platelets count ≥100x109/L, hemoglobin ≥80 g/L)
  8. Accepted renal functions. (BUN & serum creatinine <1.5x upper limit of normal value with normal GFR).
  9. Accepted liver functions. (total bilirubin and direct bilirubin < 1.5 x ULN & alanine aminotransferase and aspartate aminotransferase < 3 x ULN)
  10. Informed consent.

Exclusion criteria

  1. Patients with distant metastatic lesions, as detected by imaging techniques.
  2. Patients with history of other head and neck malignancies.
  3. Patients with history of previous head and neck irradiation.
  4. Patients with a serious concomitant illness, such as active cardiac disease, severe uncontrolled hypertension, or uncontrolled infection.
  5. Women who are pregnant or breast feeding.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

63 participants in 2 patient groups

Hypofractionated dose escalated VMAT
Experimental group
Description:
Hypofractionated dose escalated VMAT radiotherapy
Treatment:
Radiation: Hypofractionated dose escalated VMAT
Conventional concurrent chemoradiation
No Intervention group
Description:
Conventional concurrent chemoradiation

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems